MicroRNA-486–dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy–associated symptoms
Matthew S. Alexander(Children's of Alabama), Louis M. Kunkel(Boston Children's Hospital), Genri Kawahara(Tokyo Medical University), Iris Eisenberg(Hadassah Medical Center), Fedik Rahimov(AbbVie (United States)), Frederic Shapiro(Northeastern University), Angela Lek(Muscular Dystrophy Association), Elicia Estrella(Boston Children's Hospital), Jamie L. Marshall(Solidus Biosciences (United States)), Peter B. Kang(Boston Children's Hospital), Molly Gasperini(University of Washington), Natássia M. Vieira(Boston Children's Hospital), Norio Motohashi(National Center of Neurology and Psychiatry), Jeffrey J. Widrick(University of Massachusetts Chan Medical School), Jennifer A. Myers(Boston Children's Hospital), Juan Carlos Casar(Pontificia Universidad Católica de Chile)
Cited by 152
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Landscape of X chromosome inactivation across human tissues
|Nature|2017|1.2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Disease-associated astrocytes in Alzheimer’s disease and aging
|Nature Neuroscience|2020|1k